Switch to
More onapp

How to use scorecard? Learn more

Aarti Pharmalabs Ltd

AARTIPHARM
Health CareLabs & Life Sciences Services
Unknown-
High RiskStock is 3.40x as volatile as Nifty
285.1510.70 (-3.62%)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Scorecard

Performance

Low

Hasn't faired well - amongst the low performers

Valuation

High

Seems to be overvalued vs the market average

Growth

Low

Lagging behind the market in financials growth

Profitability

High

Showing good signs of profitability & efficiency

Entry point

Avg

The stock is overpriced but is not in the overbought zone

Red flags

Low

No red flag found

How to use scorecard? Learn more

Health CareLabs & Life Sciences Services
Unknown-
High RiskStock is 3.40x as volatile as Nifty

Key MetricsEdit

No LabelNo Label
PB RatioPB Ratio
0
Dividend YieldDiv. Yield
Sector PESector PE
33.16
Sector PBSector PB
4.01
Sector Div YldSctr Div Yld
0.97%

Forecast & RatingsDetailed Forecast 

Forecast data is currently unavailable for this stock

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Aarti Pharmalabs Limited is a manufacturer of active pharmaceutical ingredients (API), pharmaceutical intermediates, new chemical entities (NCE), and xanthine derivatives situated in India. The Company delivers contract development and manufacturing organization (CDMO) services for drug substance/NCE development and manufacturing for pharmaceutical and biotech firms with a focus on the Ph-I/II/III, launch, and commercial phases. It has dedicated facilities for the production of corticosteroids, cytotoxic medicines, and oncology products. Its range of API products include Ramipril, Quinapril HCL, Budesonide, Bambuterol HCL, Apixaban, Rivaroxaban, Cinacalcet and others. Its range of intermediate products include Abemaciclib Intermediate, Acalabrutinib Intermediate, Afatinib Intermediate, Apalutamide Intermediate, Azathioprine Intermediate, Bosutinib Intermediate and others. Its xanthine and allied products include theophylline anhydrous, aminophylline, etophylline, and theophylline.

Financial TrendFinancial statements 

2020202120220.000.001.20-0.000.000.12
Revenue
Profit
Loss
All values in ₹ Thousand cr.
See financial statements

Holdings TrendDetailed holdings 

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

See detailed holdings

Recent NewsAll news 

Hmm, looks like data is unavailable here. Please come back after some time
See all news

Recent EventsAll events 

Credit Rating 
Announced OnMar 3, 2023

Aarti Pharmalabs Limited has informed the Exchange about Credit Rating | Download

Aarti Pharmalabs Limited has informed the Exchange about Credit Rating | Download

Financial Result Updates 
Announced OnFeb 13, 2023

Aarti Pharmalabs Limited has submitted to the Exchange, the financial results for the period ended December 31, 2022. | Download

Aarti Pharmalabs Limited has submitted to the Exchange, the financial results for the period ended December 31, 2022. | Download

See all events